CPH share price, page-109

Hi @AmbiGuity

I'm back from my holiday and would like to report to my parole officer that I contacted HHI again and found out that the high concentration CBD oils work best for retractable epilepsy. I think we all knew that.

I was also informed that "Patients using medical cannabis should be aware that THC may show up in roadside tests depending on the equipment. As a golden rule it is best to wait til 8 hours after the last dose."

The high concentration THC oil is mainly used for PTSD patients and prescriptions are issued at the doctors discretion.

If you want pictures of the product you will need to email them at HHI because I can't seem to be able to copy it onto this forum, ( just due to my lack of computer competence), The guy I have been in contact with will answer any questions, but he only answers the questions that are asked.

PS: I am glad that some other posters are starting to add real content to this forum. Keep up the good work.

My contact sent me this, but I don't know where it is from. A close friend of mine has PTSD as a result of a couple of stints in Afghanistan, but I haven't been able to convince his wife that he may need this product.

Schweik


Post-Traumatic Stress
Post-traumatic stress disorder (PTSD) is a psychiatric health response to a traumatic event.
Symptoms of post-traumatic stress may include flashbacks, nightmares, and severe anxiety, as
well as uncontrollable thoughts about the event. These symptoms may persist long after the
triggering event, and may be unresponsive to conventional therapeutic treatments. An estimated
one in ten Americans suffers from post-traumatic stress.
The endogenous cannabinoid system is believed to play a "critical role ... in the etiology of PTSD
in humans."[1] Researchers theorize, "Cannabis may dampen the strength or emotional impact of
traumatic memories through synergistic mechanisms that might make it easier for people with
PTSD to rest or sleep and to feel less anxious and less involved with flashback memories. ...
Evidence is increasingly accumulating that cannabinoids might play a role in fear extinction and
anti-depressive effects."[2]
Placebo-controlled clinical data assessing cannabis' impact on PTS is not yet available; however,
gold-standard clinical trials are now underway in both the United States and Canada to assess
the safety and efficacy of cannabis therapy for this condition.[3-4]
Available observational data provides somewhat mixed results. A retrospective review of
patients' symptoms published in 2014 in the Journal of Psychoactive Drugs reported a greater
than 75 percent reduction CAPS (Clinician Administered Posttraumatic Scale) symptom scores
following cannabis therapy.[5] But a larger observational study of PTS subjects reported that
"those who never used marijuana had significantly lower symptom severity four months later than
those who continued or started use after treatment."[6] Similarly, a 2015 case-control study found
no association between self-reported cannabis use and mental health symptom severity in a
cohort of Veterans with probable PTSD.[7] As a result, experts presently advise physicians to "use
their own clinical judgment when weighing the potential risks and benefits for a particular
patient."[8]
Small clinical trials assessing the use of individual cannabinoids have shown success in PTS
treatment. A 2014 Israeli trial reported that the adjunctive administration of orally absorbable
THC "caused a statistically significant improvement in global symptom severity, sleep quality,
frequency of nightmares, and PTSD hyperarousal symptoms" in a cohort of ten
subjects.[9] Separate trials report that the administration of nabilone, a synthetic cannabinoid,
safely mitigates various symptoms of post-traumatic stress, including insomnia, chronic pain, and
treatment-resistant nightmare.[10-11]
Consequently, some investigators now believe that targeting the endogenous cannabinoid
system may "provide a foundation upon which to develop and validate informative biomarkers of
PTSD vulnerability, as well as to guide the rational development of the next generation of
evidence-based treatments for PTSD.[12]
REFERENCES
[1] Nuemeister et al. 2013. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress
disorder: a positron emission tomography study. Molecular Psychiatry 18: 1034-1040
[2] Passie et al. Mitigation of post-traumatic stress symptoms by cannabis resin: A review of the clinical and
neurobiological evidence. Drug Testing and Analysis 4: 649-659
[3] Vancouver Sun. September 13, 2016. "B.C. Scientists launch research trial into effects of marijuana on
PTSD."
[4] The Leaf Online. April 27, 2016. "PTSD cannabis study to finally move ahead."
[5] Greer et al. 2014. PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis
Program.Journal of Psychoactive Drugs 46: 73-77.
[6] Medscape. December 15, 2004. "Medical marijuana may worsen PTSD symptoms, increase violence."
[7] Johnson et al. Mental health symptom severity in cannabis using and non-using Veterans with probable
PTSD.Journal of Affective Disorders 190: 439-442.
[8] Stephanie Yarnell. 2015. The use of marijuana in post traumatic stress disorder: A review of the current
literature. The Primary Care Companion for CNS Disorders 17 [E-pub ahead of print].
[9] Roitman et al. 2014. Preliminary, open-label, pilot study of add-on oral delta-9- tetrahydrocannabinol in
chronic post-traumatic stress disorder. Clinical Drug Investigation 34: 587-591.
[10] Cameron et al. 2014. Use of a synthetic cannabinoid in a correctional population for posttraumatic
stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a
retrospective evaluation. Journal of Clinical Psychopharmacology 34: 559-564.
[11] Fraser G. 2009. The use of a synthetic cannabinoid in the management of treatment-resistant
nightmares in posttraumatic stress disorder (PTSD). CNS